n,n-dimethylarginine has been researched along with obeticholic acid in 1 studies
| Studies (n,n-dimethylarginine) | Trials (n,n-dimethylarginine) | Recent Studies (post-2010) (n,n-dimethylarginine) | Studies (obeticholic acid) | Trials (obeticholic acid) | Recent Studies (post-2010) (obeticholic acid) |
|---|---|---|---|---|---|
| 2,216 | 228 | 1,221 | 348 | 27 | 320 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adorini, L; Berardo, C; Di Pasqua, LG; Ferrigno, A; Richelmi, P; Rizzo, V; Siciliano, V; Vairetti, M | 1 |
1 other study(ies) available for n,n-dimethylarginine and obeticholic acid
| Article | Year |
|---|---|
The farnesoid X receptor agonist obeticholic acid upregulates biliary excretion of asymmetric dimethylarginine via MATE-1 during hepatic ischemia/reperfusion injury.
Topics: Animals; Antiporters; Arginine; Biliary Tract; Blotting, Western; Carrier Proteins; Chenodeoxycholic Acid; Liver Diseases; Male; Nitric Oxide Synthase; Organic Cation Transport Proteins; Protein-Arginine N-Methyltransferases; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Receptors, Cytoplasmic and Nuclear; Reperfusion Injury; RNA, Messenger; Up-Regulation | 2018 |